期刊
CLINICAL INFECTIOUS DISEASES
卷 58, 期 10, 页码 1439-1448出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciu069
关键词
extended-spectrum beta-lactamases; carbapenemases; AmpC beta-lactamases; Acinetobacter baumannii; Pseudomonas aeruginosa
资金
- Thrasher Research Foundation
Antibiotic resistance in conjunction with the erosion of the drug development pipeline may lead us into a bleak future, a post-antibiotic era.Because of a shortage of studies addressing treatment options for multidrug-resistant Gram-negative (MDRGN) infections in children, data must be extrapolated from the adult literature. However, even adult studies are limited by significant methodological flaws. We are in urgent need of pediatric specific pharmacokinetic/pharmacodynamic data for agents with activity against MDRGN infections as well as improved clinical outcomes studies. For the time being, we must rely on in vitro studies, observational data, and clinical experience to guide our therapeutic decisions. In this review, we discuss treatment considerations for infections caused by extended-spectrum beta-lactamase-producing organisms, AmpC beta-lactamase-producing organisms, carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii in the pediatric population.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据